Antimalarial Napthylisoquinoline Alkaloids And Pharmaceutical Compositions And Medicinal Uses Thereof
Posted Jun 13 2010 5:00pm
Description of Invention: This invention provides new napthylisoquinoline alkaloid compounds, and compositions and methods of use of known and new napthylisoquinoline alkaloids, for treatment or prevention of malaria. Some compounds of this class occur naturally in plant species of the Ancistrocladaceae and Dioncophyllaceae plant families which are found in tropical Africa and southern and southeast Asia. The compounds exhibit effective antimalarial properties and offer important new weapons in the treatment of this devastating disease. The deadliest malarial parasites have become resistant to previously effective antimalarial drugs; therefore, effective new antimalarial drugs are urgently needed. These new naphthylisoquinoline compounds effectively inhibit the growth, reproduction, and pathologic effects of a broad spectrum of Plasmodia parasites, including drug-resistant strains.
Portfolios: Infectious Diseases Infectious Diseases - Therapeutics In-vitro Data
For Additional Information Please Contact: Admin. Licensing Spec-InfectDis NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: anos@mail.nih.gov Phone: 301-496-7057 Fax: 301-402-0220
Description of Invention:
This invention provides new napthylisoquinoline alkaloid compounds, and compositions and methods of use of known and new napthylisoquinoline alkaloids, for treatment or prevention of malaria. Some compounds of this class occur naturally in plant species of the Ancistrocladaceae and Dioncophyllaceae plant families which are found in tropical Africa and southern and southeast Asia. The compounds exhibit effective antimalarial properties and offer important new weapons in the treatment of this devastating disease. The deadliest malarial parasites have become resistant to previously effective antimalarial drugs; therefore, effective new antimalarial drugs are urgently needed. These new naphthylisoquinoline compounds effectively inhibit the growth, reproduction, and pathologic effects of a broad spectrum of Plasmodia parasites, including drug-resistant strains.
Inventors:
Michael R Boyd (NCI)
Patent Status:
HHS, Reference No. E-090-1994/0
US, , Patent No. 5,639,761, Issued 17 Jun 1997
US, , Patent No. 6,627,641, Issued 30 Sep 2003
HHS, Reference No. E-090-1994/0
PCT, Application No. PCT/US95/01717 filed 13 Feb 1995
Portfolios:
Infectious Diseases
Infectious Diseases - Therapeutics
In-vitro Data
For Additional Information Please Contact:
Admin. Licensing Spec-InfectDis
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: anos@mail.nih.gov
Phone: 301-496-7057
Fax: 301-402-0220
Ref No: 157
Updated: 06/2010